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Functional magnetic resonance imaging (fMRI) techniques can be used to assess
cerebrovascular dysfunction in Alzheimer’s disease, an important and early contributor
to pathology. We hypothesized that bradykinin receptor inhibition alleviates the vascular
dysfunction in a transgenic arcAβ mouse model of cerebral amyloidosis and that
fMRI techniques can be used to monitor the treatment response. Transgenic arcAβ
mice, and non-transgenic littermates of 14 months-of-age were either treated with the
bradykinin receptors 1 and 2 blocker noscapine or received normal drinking water as
control over 3 months (n = 8–11/group) and all mice were assessed using fMRI at the
end of the treatment period. Perfusion MRI using an arterial spin labeling technique
showed regional hypoperfusion in arcAβ compared to non-transgenic controls, which
was alleviated by noscapine treatment. Similarly, measuring cerebral blood volume
changes upon pharmacological stimulation using vessel dilator acetazolamide revealed
recovery of regional impairment of cerebral vascular reactivity in arcAβ mice upon
noscapine treatment. In addition, we assessed with immunohistochemistry beta-
amyloid (Aβ) and inflammation levels in brain sections. Immunohistological stainings for
Aβ deposition (6E10) and related microgliosis (Iba1) in the cortex and hippocampus were
found comparable between noscapine-treated and untreated arcAβ mice. In addition,
levels of soluble and insoluble Aβ38, Aβ40, Aβ42 were found to be similar in brain
tissue homogenates of noscapine-treated and untreated arcAβ mice using electro-
chemiluminescent based immunoassay. In summary, bradykinin receptors blockade
recovered cerebral vascular dysfunction in a mouse model of cerebral amyloidosis. fMRI
methods revealed the functional deficit in disease condition and were useful tools to
monitor the treatment response.
Keywords: Alzheimer’s disease, beta-amyloid, bradykinin receptor, cerebral blood volume, cerebrovascular
dysfunction, magnetic resonance imaging, perfusion imaging
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form of
dementia and represents a complex and multi-factorial
disorder. Hallmarks of the disease are the accumulation
of abnormal beta-amyloid (Aβ) and neurofibrillary tangles
composed of hyperphosphorylated microtubule-associated
tau protein, leading to neurodegeneration (Braak and Braak,
1991). Misfolded Aβ and tau protein bind to receptors on
microglia and astroglia, and trigger innate immune responses,
which contribute to disease progression and severity (Heneka
et al., 2015). In addition, alterations in the density and
morphology of cerebral vasculature, a regional reduction of
cerebral blood flow (CBF) and an impaired cerebral vascular
reactivity (CVR) have been reported in patients with AD
and mild cognitive impairment (de la Torre, 2004; Kisler
et al., 2017), and have been implicated to contribute to the
cognitive impairment.
Several neuroimaging techniques have been developed to
assess features of AD pathology in patients and animal models
of the disease. The quest is to improve the diagnosis of the
disease, to assess the disease stage, to select patients for treatment
and to monitor the response to therapy. Among them, magnetic
resonance imaging (MRI) has been used to detect degenerative
changes in patients with AD (Frisoni et al., 2010). More recently,
functional MRI (fMRI) techniques have been implemented to
evaluate cerebrovascular abnormality in patients with AD, which
has been shown to occur early during the disease course (Iturria-
Medina et al., 2016). These comprise regional changes in CBF
(Maier et al., 2014) and microvessel density (Klohs et al.,
2012), disturbances of blood–brain barrier integrity (Montagne
et al., 2017), impairment of vascular reactivity (Stoppe et al.,
1995; Mueggler et al., 2002; Princz-Kranz et al., 2010; Dumas
et al., 2012), and vascular remodeling (Dumas et al., 2012;
Klohs et al., 2016).
The kallikrein-kinin system has been implicated as an
important pathophysiological mediator of cerebral vascular
dysfunction, neuroinflammation and Aβ pathology in AD
(Schmaier, 2016; Nokkari et al., 2018). Kinins, in particular
bradykinin, are pro-inflammatory mediators with a range of
physiological effects in the periphery, which have also been
described in the central nervous system (Couture et al., 2000).
Bradykinin, lysine-bradykinin, and bradykinin degradation
products act through the activation of two G protein-coupled
bradykinin receptors (BRs): B1R and B2R. Pharmacological
antagonism or genetic deletion of B1R (Prediger et al., 2008;
Lacoste et al., 2013; Passos et al., 2013; Asraf et al., 2016) and
B2R (Bicca et al., 2015; Caetano et al., 2015) have been shown
to alleviate the cognitive deficits in Aβ-injected or transgenic AD
animal models.
In the present study, we hypothesized that chronic oral
treatment with the phthalideisoquinoline alkaloid noscapine,
a B1R and B2R antagonist (Landen et al., 2004), ameliorates
the CBF and CVR abnormalities in arcAβ mouse model of
amyloidosis (Merlini et al., 2011). We investigated the effect
of BR blockade by noscapine on CBF and CVR in arcAβ
mice using fMRI techniques. In addition, we studied the
effects of noscapine treatment on Aβ deposits and microglia by
immunohistochemical and biochemical analysis.
MATERIALS AND METHODS
Animals
All experiments were performed in accordance with the Swiss
Federal Act on Animal Protection and were approved by the
Cantonal Veterinary Office Zurich (Permit Number: 90-2016).
All procedures fulfilled the ARRIVE guidelines on reporting
animal experiments. ArcAβ transgenic mice, with human
APP695 transgene containing the Swedish (K670N/M671L) and
Arctic (E693G) mutation under the control of the prion protein
promoter (Knobloch et al., 2007), were used. Animals were
kept in a temperature-controlled room in individually ventilated
cages under 12 h light/dark cycle and access to pelleted food
and water were provided ad libitum. Paper tissue was given as
environmental enrichment. A sample size of n = 7 per group was
calculated for the primary end point CBF, a fixed effect omnibus,
one-way ANOVA with four groups, and an effect size f = 0.72,
α = 0.05 and β = 0.2. Consequently, group sizes n > 7 were used
(G∗power, University of Düsseldorf, Germany).
Measurement of Plasma Bradykinin
Levels
Six arcAβ and seven non-transgenic littermates (NTLs) of
17 months-of-age were used. Blood from the vena cava of
the mice was collected into Eppendorf tubes filled with 50 µl
0.5 M ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich
GmbH, Switzerland) and centrifuged at 4◦C, 1000 g for 15 min.
The blood : EDTA volume ratio was approximately 8:1. The
plasma supernatants were collected as 50 µl aliquots, frozen
and kept at −80◦C, until use. The enzyme immunoassay
(RayBiotech, Norcross, GA, United States) was used for
bradykinin level measurement. A known concentration of
biotinylated bradykinin was spiked into samples and standards,
which were then added to wells. Here, biotinylated-bradykinin
competes with the endogenous bradykinin in plasma for binding
to the monoclonal anti-bradykinin antibody immobilized on
the wall. After color development reaction, the intensity of the
colorimetric signal was directly proportional to the amount
of biotinylated bradykinin captured by the antibody, which
inversely correlated to the amount of endogenous peptide in
the sample or standard. A standard curve for the quantification
of bradykinin concentration in the samples was generated. The
lower detection limit of the assay was 1.4 ng/ml bradykinin.
Study Design Noscapine Treatment
A flowchart of the design for the noscapine treatment study
is shown in Supplementary Figure 1. Twenty arcAβ and 17
NTLs of both genders at approximately 14 months-of-age (at the
start of the study) were used for the 3 months treatment study
(Table 1). Animals of both genders were randomly allocated to
experimental groups. Experimenters were blinded during data
acquisition and analysis. Mice in the treatment arm were supplied
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TABLE 1 | Demographic information, weight, and blood pressure of mice.
Group NTL NTL noscapine arcAβ arcAβ noscapine
N 8 9 9 11
Female/male 4/4 7/2 5/4 4/7
Age (months)∗ 16.6 ± 0.3 16.8 ± 0.4 16.6 ± 0.4 16.6 ± 0.4
Weight before treatment (g) 31.5 ± 4.3 28.1 ± 3.8 26.8 ± 4.7 29.1 ± 3.1
Weight end of treatment (g) 32.5 ± 4.6 28.3 ± 2.6 28.1 ± 4.4 29.3 ± 3.6
Systolic blood pressure (bpm) 86.3 ± 24.8 117.4 ± 16.0 107.8 ± 36.4 108.2 ± 22.6
Diastolic blood pressure (bpm) 61.8 ± 29.0 76.2 ± 11.9 75.1 ± 43.1 76.7 ± 24.7
Data is shown as mean ± standard deviation; ∗at the end of the treatment period; weight and blood pressure analyzed by two-way ANOVA with Tukey’s post hoc analysis;
age analyzed by one-way ANOVA with Tukey’s post hoc analysis, NTL, non-transgenic littermates.
with noscapine (Sigma-Aldrich GmbH, Switzerland) in acidified
drinking water for 3 months before the first measurement.
Noscapine (3 g/l) was dissolved in double distilled water, adjusted
to pH 3.5 (Sigma-Aldrich GmbH, Switzerland). Prior to the
treatment study, high performance liquid chromatography was
performed to measure the stability of noscapine in acidified
double distilled water (pH 3.5), where 94 and 70% of noscapine
were detectable after 24 h and 2 days, respectively. Therefore, we
prepared fresh noscapine solution (pH 3.5) daily and protected
it from light to ensure stability. For the control group, double
distilled water was provided. All animals were weighed once
per week during the study. Blood pressure of the mice were
assessed non-invasively at the end of the treatment by tail-
cuff using CODA monitor (Kent Scientific, Corp., Torrington,
CT, United States). Systolic and diastolic blood pressures of
each mice were assessed consecutively twenty times, and were
averaged (Table 1).
Functional Magnetic Resonance Imaging
All MRI scans were performed on a 7/16 small animal
MR Pharmascan (Bruker Biospin GmbH, Ettlingen, Germany)
equipped with an actively shielded gradient set of 760 mT/m
with a 80 µs rise time and operated by a Paravision 6.0 software
platform (Bruker Biospin GmbH, Ettlingen, Germany). Mice
were anesthetized with an initial dose of 4% isoflurane (Abbott,
Cham, Switzerland) in oxygen/air (200/800 µl/min) mixture and
anesthesia were maintained at 1.5% isoflurane in oxygen/air
(100/400 µl/min) mixture. Mice were placed in prone position
on a water-heated support to keep body temperature within
36.5 ± 0.5◦C. Body temperature was monitored with a rectal
temperature probe.
Perfusion MRI was performed using an arterial spin labeling
technique as described previously (Ni et al., 2018a). The Paxinos
mouse brain atlas was used as anatomical reference for scan
positioning and analysis (Paxinos and Franklin, 2012). Re-
assessment of CBF (test–retest analysis) was performed in
17 mice randomly selected from the groups for assuring the
repeatability of the CBF measurement (n = 17).
Cerebral vascular reactivity was assessed, after a 1 week of
recovery following perfusion MRI, by measuring cerebral blood
volume (CBV) changes upon pharmacological stimulation using
vessel dilator acetazolamide, as previously reported (Mueggler
et al., 2002; Princz-Kranz et al., 2010). The scanner was
equipped with a 300 MHz cryogenic radiofrequency probe
for conducting the CVR assay. Mice were endotracheally-
intubated and maintained at 1.5% isoflurane in oxygen/air
(100:400 µl/min) mixture and actively ventilated at a rate
of 90 breaths/minute and a tidal volume of approximately
0.3 µl/breath using a small animal ventilator (MRI-1, CWE,
Inc., United States). Animal’s tail veins were cannulated for
administration of drugs and contrast agent. A neuromuscular
blocking agent gallanmine triethiode (Sigma-Aldrich GmbH,
Switzerland) was administered twice as a bolus (40 µl, 7 mg/ml)
at the beginning and before i.v. injection of contrast agent
while the isoflurane level was reduced to 1.2%. T2-weighted
anatomical reference images were acquired using a spin echo
rapid acquisition with relaxation enhancement (RARE) sequence
with the same anatomical geometry as RARE sequence at
pre- and post-injection of vessel dilator acetazolamide. Fifteen
minutes after injection of contrast agent, of gallanmine was
injected i.v. (21 mg/kg body weight). Then, eight sequential
pre-contrast agent scans at baseline signal intensity Spre (CBV0
image) were acquired using a RARE sequence: temporal
resolution = 40 s, repetition time = 3333 ms, echo time eff = 81 ms,
RARE factor = 32, field-of-view = 20 mm × 20 mm, imaging
matrix = 133 × 103, slice thickness = 1 mm, 1.5 mm gap,
resolution = 150 µm × 200 µm. FLASH sequence NR = 50
was used for ensuring the successful injection of the contrast
agent. After 10 repetitions, iron oxide contrast agent Endorem
(50 mg Fe/kg body weight, Guerbet SA, Roissy-en-France,
France) was administered i.v. A RARE sequence was started
after 5 min after repetition = 100 and 8 averages, when the
contrast agent concentration had reached steady state. After
the 30th repetition (20 min), acetazolamide (30 mg/kg body
weight; Diamox R© parenteral, Goldshield Pharmaceuticals, Ltd.,
Croydon, United Kingdom) was administered i.v. as a bolus.
Additional 70 images were collected (46.7 min), yielding the
image series S(t).
Brain Tissue Collection
After MRI, mice were anesthetized under
ketamine/xylazine/acepromazine maleate (75/10/2 mg/kg
body weight, bolus injection, i.p.). Mice were perfused using cold
PBS (pH 7.4). Brains were removed from the skull. The left brain
hemispheres were fixed in 4% paraformaldehyde (Sigma-Aldrich,
Switzerland) in PBS (pH 7.4) at 4◦C and embedded in paraffin
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following routine procedures. The right hemispheres were snap
frozen and stored at−80◦C, until use.
Meso Scale Discovery (MSD) Analysis
Meso Scale Discovery (MSD) analysis was performed as
described previously (Kulic et al., 2012) in NTL (n = 6), NTL
noscapine (n = 8), arcAβ (n = 7), and arcAβ noscapine (n = 4)
mice. In brief, frozen brain tissues were homogenized using a
glass Teflon homogenizer with homogenization buffer containing
100 mM Tris-HCl, 150 mM NaCl and complete EDTA-free
protease inhibitor cocktail (Roche Diagnostic, Risch-Rotkreuz,
Switzerland). The amount of buffer used was equivalent to 10-
fold wet weight of the brain tissue. The brain homogenates were
centrifuged at 100,000 g for 1 h and supernatants were collected
Tris-buffered saline (TBS) fraction and pellets were homogenized
again in homogenization buffer containing 2% of sodium dodecyl
sulfate (SDS). Centrifugation was repeated and the supernatants
(SDS-fraction) were again collected. The remaining pellet was
suspended in 70% formic acid (FA), sonicated four times for
30 s at 30% power and again centrifuge at 100,000 g for 30 min.
The supernatants were collected (FA-fraction), lyophilized and
reconstituted in homogenization buffer. Aβ38, Aβ40, and Aβ42
levels were measured in the abovementioned brain homogenate
fractions using an MSD 3plex multi-SPOT Aβ human kit
(Gaithersburg, MD, United States). Plates were measured on
an MSD SECTOR Imager 600 plate reader (Gaithersburg, MD,
United States). The MSD DISCOVERY WORKBENCH software
(Version 3.0.18) (Gaithersburg, MD, United States) with Data
Analysis Toolbox was used to calculate sample concentrations by
comparing them against a standard curve.
Immunohistochemistry
Cy3-6E10 (mouse anti-Aβ-SIG-39320, Signet Laboratories,
United States, 1:5000 dilution) and Alexa488-ionized calcium-
binding adapter molecule (Iba1, Rabbit anti-Iba1, Wako
Chemicals, United States, HRP Rabbit AK, 1:2500 dilution)
immunostainings were done on 5µm brain sections as previously
described (Spani et al., 2015). Nuclei were counterstained by
DAPI, while adjacent sections were stained with hematoxylin and
eosin. Images were examined using Leica DM 4000B microscopy
with Olympus DP71 digital camera and VIS (Visiopharm
Integrator System) version 4.4.6.9 software at 5×, 10×, 20×,
and 40× magnification. Images were captured on each slices at
(× 5, 10, 20, 40 magnification). Quantification of the images
was performed blinded using Image J (NIH, United States).
For quantitative image analysis, the cortex and hippocampus
were analyzed on three equidistant sagittal hemibrain sections
of each mouse (interaural lateral 0.60 to 0.72 mm) at 10×, three
images taken at each region on one slice. Images of the cortex
and hippocampus were taken with an exposure time of 200 ms
(amyloid, 6E10-Cy3), 308 ms (microglia, Iba1-Alexa488), 30 ms
(nucleus, DAPI) of the same areas. The Paxinos mouse brain atlas
was used as anatomical reference (Paxinos and Franklin, 2012).
Threshold and particle analysis functions were applied, resulting
in Aβ and microglia covered area in percentage.
Data Analysis
Two persons performed data analysis independently, and the
obtained results were averaged. CBF maps from arterial spin
labeling data was computed as previously described (Ni et al.,
2018a). Region of interest (ROIs) were evaluated in the
cerebral cortex, hippocampus and thalamus using AFNI (NIH,
United States) with T2-weighted anatomical scan and the Paxino
mouse brain atlas as reference (Paxinos and Franklin, 2012).
Figure 2A shows the placement of the ROIs on the anatomical
scans, which were transferred to the CBF map. CBF in ROIs was
calculated from both T1 values (Zerbi et al., 2014) using MATLAB
R2015b (The Mathworks, Natick, MA, United States):
CBF/λ = T1 global
T1 blood
(
1
T1 selective
− 1
T1 global
) (1)
where λ is the blood/tissue partition coefficient for water,
assumed to be 0.9 µl/g (Leithner et al., 2008) and T1 blood was
assumed to be 2.007 s at 7 T (Zhang et al., 2013).
Assessment of CVR was performed using Biomap 6 (Novartis
Institute for Biomedical Research, Basel, Switzerland). The ROIs
were defined in six brain regions (motor cortex, sensory cortex,
striatum, hippocampus, thalamus, and cerebellum). Baseline
CBV (CBV0) was calculated for each ROI. The baseline CBV
and relative percentage changes of CBV versus baseline CBV
(1CBV(t)) were computed on a pixel-by-pixel basis according to:
1CBV%(t) = 1CBV(t)CBV0 × 100 =
ln (S(t))/ ln(S0)
ln (S0)/ ln(Spre)
× 100 (2)
CBV0 = − ln( TT0 ) = − ln(mean Post CAmean Pr e CA )
(3)
sqrt(1CBV%(t)) = a× time+ b (4)
Linear regression analysis was performed on the square root of
the 1CBV% (t),sqrt(1 CBV% (t)) with time. ROIs of specific
brain regions in the left and right hemispheres were merged
into one ROI. Figure 3A shows the placement of the ROIs for
analyzing the CBV data using T2-weighted anatomical scan and
the Paxino mouse brain atlas as reference (Paxinos and Franklin,
2012). The response time curve1CBV (t) and the late1CBV(%)
of slices 90–100 (40–46.7 min) were compared between groups.
Statistical Analysis
For comparison of the continuous numeric data such as weight,
blood pressure before and after treatment, a two-way ANOVA
with Tukey’s post hoc analysis (GraphPad Prism 6.0, San Diego,
CA, United States) was used. For comparison of age between
groups, a one-way ANOVA with Tukey’s post hoc analysis
was used. For comparison of bradykinin plasma level between
NTLs and arcAβ mice, unpaired t-test was used after Shapiro–
Wilk normality test. For group comparison of CBF, CBV0, late
1CBV(%), slope of sqrt(1CBV%(t)) and immunostaining of
Aβ and Iba1 in multiple brain regions, two-way ANOVA with
Turkey’s post hoc analysis were used. For MSD measurement of
Aβ level in different brain fractions of test–retest analysis of the
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CBF data of the same mice, a Pearson correlation analysis was
performed. All data are present as mean ± standard deviation.
Significance was set at ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001.
RESULTS
Demographics and Blood Pressure
Demographic information, body weight before/after the
treatment and blood pressure are summarized in Table 1
including NTL (n = 8), NTL noscapine (n = 9), arcAβ (n = 9),
and arcAβ noscapine (n = 11). One-way ANOVA showed
that groups did not differ in terms of age among the groups
(approximately 16.6 months-old after the treatment), F(DFn,
DFd): F(3,33) = 0.4467, p = 0.7212. And no differences between
body weights before and after the treatment period were found
between groups F(3,66) = 0.104, p = 0.9574. As inhibitors of BRs
can affect the angiotensin system (AbdAlla et al., 2001; Jing et al.,
2012), we measured the systolic and diastolic blood pressure
in mice at the end of the treatment period. Blood pressure was
not statistically different between noscapine-treated NTLs, and
arcAβ mice compared to untreated groups F(3,33) = 0.1594,
p = 0.9229 (Table 1).
Increased Plasma Levels of Bradykinin
1–5 in arcAβ Mice
We tested with enzyme immunoassay if kallikrein-kinin system is
activated in the arcAβ mouse model of amyloidosis. We detected
that arcAβmice have higher levels of circulating bradykinin in the
plasma, as compared to NTLs (33.2± 10.5 vs. 20.3± 7.43 ng/ml,
p = 0.0338, Shapiro–Wilk p = 0.2514 and p = 0.3587 respectively,
passing normality test) (Figure 1).
Noscapine Treatment Ameliorated
Regional Hypoperfusion
We first tested the effect of chronic oral noscapine treatment
on cerebral perfusion of arcAβ mice. Figure 2A shows the
FIGURE 1 | Bradykinin levels in the plasma of arcAβ mice and non-transgenic
littermates (NTLs) measured by using enzyme immunoassay. ArcAβ mice
(n = 6) have higher levels of circulating bradykinin, as compared to NTL
(n = 6); ∗p < 0.05, unpaired Student’s t-test; Shapiro–Wilk p = 0.2514 and
p = 0.3587, respectively passing normality test.
placement of acquisition slice and ROIs of CBF analysis on
the structural MRI image. Figure 2B shows representative
coronal CBF maps for all four groups of mice. Regional analysis
of the perfusion MRI data showed the interaction between
brain region and treatment × genotype with F(DFn,DFd):
F(6,186) = 2.316, p = 0.0351; reduced CBF in the cortex
(123.0 ± 40.8 vs. 165.4 ± 31.1 µl/100 g/min, p = 0.0192) and
thalamus (154.1± 61.1 vs. 200.5± 38.4 µl/100 g/min, p = 0.0065)
in untreated arcAβ mice compared to untreated NTLs were
observed (Figure 2C). Noscapine-treated arcAβ mice showed
significantly higher CBF values in the cortex (167.6 ± 33.9
vs. 123.0 ± 40.8 µl/100 g/min, p = 0.0023) and thalamus
(196.3 ± 43.8 vs. 154.1 ± 61.1 µl/100 g/min, p = 0.0043)
compared to untreated arcAβ mice. The test–retest results of two
perfusion MRI measurements in the same mice are shown in
Supplementary Figure 2. Pearson correlation analysis showed a
robust correlation (r = 0.9491, p < 0.0001, n = 17) between test
and re-test measures. Taken together, perfusion imaging revealed
that noscapine treatment mitigated the hypoperfusion seen in
arcAβ mice of this age.
Noscapine Treatment Mitigated Impaired
CVR
We then tested the effect of noscapine treatment on the
CVR by measuring CBV after stimulation with vessel dilator
acetazolamide. One mouse in the un-treated NTLs, noscapine-
treated NTLs and noscapine-treated arcAβ group showed
negative 1CBV and were categorized as outliers and thus
excluded from further analysis. Figure 3A illustrated the ROIs
drawing on four different levels of MR slices identified using
the Paxinos mouse brain atlas for CBV analysis (Paxinos
and Franklin, 2012). Figure 3B illustrated the representative
1CBV of different anatomical levels of mice at 46 min
after-the injection of acetazolamide (t = 0 min) overlaid
with corresponding T2-weighted MRI. No difference was
observed in baseline CBV0 values among groups [two-way
ANOVA with Tukey’s post hoc analysis, F(15,186) = 0.1919,
Supplementary Figure 3].
In Figure 4 the change in 1CBV is plotted as a function
of time for the four groups of mice (t = −20 min: contrast
agent injection; t = 0 min: acetazolamide stimulus). Linear
regression analysis were performed on sqrt (%1CBV) with time
(0–46.7 min). Two way ANOVA with Tukey’s post hoc analysis
showed significant interaction F(15,222) = 11.92, p< 0.0001. The
slope and intercept and goodness of the fitting are summarized in
Table 2. A flatter slope of sqrt(%1CBV(t)) was observed in the
motor cortex (p< 0.001), sensory cortex (p< 0.001) of untreated
arcAβ compared to untreated NTLs. A significantly steeper slope
was observed for noscapine-treated arcAβ compared to untreated
arcAβ mice in the motor cortex (p = 0.0096), sensory cortex
(p< 0.0001), and thalamus (p = 0.0161).
Two-way ANOVA with Tukey’s post hoc analysis showed the
interaction between brain region and treatment× genotype with
F(15,2244) = 8.3167, p< 0.0001; significantly reduced late1CBV
(average of t = 40–46.7 min) was observed in untreated arcAβ
mice compared to untreated NTLs in the motor cortex (12.5± 8.3
vs. 28.9 ± 26.1%, p < 0.0001), sensory cortex (24.0 ± 15.1 vs.
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FIGURE 2 | Bradykinin receptor blockade by noscapine alleviates regional hypoperfusion in arcAβ mice. (A) Anatomical position of slice for arterial spin labeling on
sagittal T2-weighted image (top) and representative regions of interest (ROI) [cortex (red), hippocampus (yellow), and thalamus (blue)] on coronal T2-weighted
anatomical image acquired at the same position (bottom). (B) Representative coronal CBF maps (approximately Bregma –1.5 ± 0.3 mm) of untreated and
noscapine-NTLs and arcAβ mice, respectively. (C) Quantification of regional CBF showed hypoperfusion in the cortex and thalamus of arcAβ compared with NTLs
that is mitigated by noscapine treatment. Data are present as mean ± standard deviation; ∗p < 0.05, ∗∗p < 0.01, two-way ANOVA with post hoc Turkey’s correction
for multiple comparison; CBF, cerebral blood flow. NTL (n = 8), NTL noscapine (n = 9), arcAβ (n = 9), arcAβ noscapine (n = 11).
30.4 ± 11.8%, p = 0.0219) (Supplementary Figure 4). Higher
late 1CBV was observed in noscapine-treated arcAβ compared
to untreated arcAβ mice in the motor cortex (24.6 ± 19.9 vs.
12.5 ± 8.3%, p < 0.0001) and hippocampus (26.9 ± 17.9 vs.
21.1 ± 10.0%, p = 0.0174). Taken together, measurements of
CBV upon acetazolamide stimulation showed that noscapine
treatment rescued the reduced CVR in cortical and subcortical
regions of arcAβ mice.
Noscapine Did Not Affect Microglia
Activation and Beta-Amyloid Level
Previous reports about the effect of B1R and B2R blockade
on neuroinflammation and Aβ load in animal models of AD
have been contradictory. We therefore analyzed microgliosis
and Aβ load in all groups of mice by immunohistochemistry
(Figure 5). Two-way ANOVA analysis indicated that noscapine
treatment had no influence on amyloid burden in the arcAβ mice
as revealed by quantitative analysis of 6E10 immunostainings
in the cortex (% 6E10 area, 1.37 ± 0.42 vs. 0.97 ± 0.44, ns)
or in the hippocampus (1.44 ± 0.83 vs. 1.09 ± 0.59, ns),
Tukey’s post hoc analysis F(1,16) = 0.004815, p = 0.9455).
Moreover, microgliosis Iba1 immunoreactivity was significantly
higher in the cortex (0.50 ± 0.32 vs. 0.19 ± 0.09, p = 0.0279)
of untreated arcAβ mice compared to NTLs, but not in the
hippocampus. The microgliosis Iba1 immunoreactivity was
similar between noscapine-treated and untreated NTLs in the
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FIGURE 3 | Bradykinin receptor blockade ameliorates the reduced regional cerebral vascular reactivity in noscapine-treated arcAβ mice. (A) Representative ROI on
coronal anatomical T2-weighted MR images at showing the motor cortex, sensory cortex, hippocampus, thalamus, striatum, and cerebellum. (B) Representative
maps of percentage change in cerebral blood volume (1CBV) of untreated and noscapine-treated NTLs and arcAβ mice. Data are present as mean ± standard
deviation; 1CBV: percentage change in CBV.
cortex (0.18 ± 0.07 vs. 0.19 ± 0.09, ns), and the hippocampus
(0.10 ± 0.07 vs. 0.21 ± 0.14, ns); and between noscapine-
treated and untreated arcAβ mice in the cortex (0.53 ± 0.07
vs. 0.50 ± 0.32, ns) and the hippocampus (0.28 ± 0.04 vs.
0.21 ± 0.14, ns) [two-way ANOVA with Tukey’s post hoc
analysis F(3,34) = 1.399, p = 0.2599]. These results suggest
that B1R and B2R blockade with noscapine at this dosage
and duration did not alter the amyloid load and degree of
Aβ-associated microgliosis.
MSD Analysis
We used MSD immunoassay to determine Aβ levels in three
protein fractions from the brain hemispheres. Two-way
ANOVA with Tukey’s post hoc analysis showed greater amount
of Aβ38 (10747.1 ± 2977.4 vs. 164.8 ± 57.8, p < 0.0001),
Aβ40 (27222.3 ± 6376.1 vs. 35.5 ± 9.0, p < 0.0001),
and Aβ42 (2679.3 ± 737.7 vs. 14.3 ± 4.7, p < 0.0001)
in FA fractions brain homogenates (Figure 6) from
arcAβ mice (n = 7) compared to NTLs (n = 6). No
significant difference was detected in the level of Aβ38,
Aβ40 and Aβ42 in TBS, SDS, and FA fractions between
noscapine-treated arcAβ mice (n = 4) and untreated arcAβ
mice (n = 7).
DISCUSSION
In the current study, we showed using fMRI techniques a
pronounced vascular dysfunction in the arcAβ mouse model
of cerebral amyloidosis. Chronic administration of B1R and
B2R antagonist noscapine ameliorated amyloidosis-associated
cerebral hypoperfusion and vascular reactivity, but did not affect
Aβ cerebral load and associated microgliosis.
Activation of the Kallikrein-Kinin System
in a Transgenic Mouse Model of Cerebral
Amyloidosis
The kallikrein-kinin system has been shown to be activated both
in patients with AD and in animal disease models (Bergamaschini
et al., 1998; Viel and Buck, 2011; Lacoste et al., 2013). In
the central nervous system, BRs are mainly distributed in the
cortex and hippocampus, the brain structures that are affected
earliest by AD pathologies (Jong et al., 2002; Ashby et al., 2012).
In the brain B1R and B2R are expressed in a variety of cells
including neurons, astrocytes, microglia, oligodendrocytes, and
endothelial cells. Upregulation of brain BR levels was shown in
rats (Viel et al., 2008), mice (Prediger et al., 2008) in response
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FIGURE 4 | Regional cerebral vascular reactivity in mouse brain. (A–F) Percent change in cerebral blood volume (1CBV) plotted as a function of time for six brain
regions (motor cortex, sensory cortex, hippocampus, striatum, thalamus, and cerebellum) of untreated and noscapine-treated NTLs and arcAβ mice, respectively.
Injection of acetazolamide at t = 0 minute. Data are present as mean ± standard deviation; ∗∗∗p < 0.001 NTL vs. arcAβ, #p < 0.05, ##p < 0.01, and ###p < 0.001
arcAβ vs. arcAβ-noscapine, two-way ANOVA with post hoc Tukey’s correction for multiple comparison. NTL (n = 8), NTL noscapine (n = 9), arcAβ (n = 9), and arcAβ
noscapine (n = 11).
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TABLE 2 | Linear regression analysis of square root (1CBV%) along with time in mice.
Region NTL NTL noscapine arcAβ arcAβ noscapine
Motor cortex Slope 0.061 ± 0.002 0.066 ± 0.002 0.048 ± 0.001∗∗∗ 0.057 ± 0.001##
Intercept 2.178 ± 0.056 1.747 ± 0.047 1.4 ± 0.023 2.379 ± 0.037
R 0.9243 0.9523 0.9773 0.9614
Sensory cortex Slope 0.064 ± 0.003 0.069 ± 0.004 0.038 ± 0.002∗∗∗ 0.054 ± 0.003###
Intercept 3.120 ± 0.087 3.383 ± 0.096 3.164 ± 0.058 2.989 ± 0.082
R 0.8462 0.8399 0.8172 0.8162
Hippocampus Slope 0.045 ± 0.002 0.047 ± 0.002 0.050 ± 0.002 0.050 ± 0.002
Intercept 2.451 ± 0.047 2.127 ± 0.055 2.503 ± 0.048 2.959 ± 0.066
R 0.9036 0.8816 0.917 0.8556
Thalamus Slope 0.042 ± 0.002 0.078 ± 0.003 0.049 ± 0.002 0.058 ± 0.002#
Intercept 2.549 ± 0.063 2.669 ± 0.090 2.690 ± 0.044 2.731 ± 0.062
R 0.8179 0.8829 0.9258 0.8999
Caudate nucleus Slope 0.054 ± 0.001 0.065 ± 0.001 0.059 ± 0.002 0.053 ± 0.002
Intercept 1.826 ± 0.032 1.327 ± 0.034 1.376 ± 0.043 1.848 ± 0.045
R 0.9666 0.9744 0.9515 0.9334
Cerebellum Slope 0.035 ± 0.003 0.045 ± 0.003 0.035 ± 0.001 0.037 ± 0.002
Intercept 3.342 ± 0.075 2.946 ± 0.075 2.619 ± 0.033 2.429 ± 0.050
R 0.6884 0.7877 0.9198 0.8486
Data is shown as mean ± standard error of the mean; ∗∗∗p < 0.001 NTL vs. arcAβ, #p < 0.05, ##p < 0.01, and ###p < 0.001 arcAβ vs. arcAβ-noscapine, two-way
ANOVA with Tukey’s post hoc analysis; NTL (n = 8), NTL noscapine (n = 9), arcAβ (n = 9), arcAβ noscapine (n = 11).
to infusion of human Aβ, as well as in transgenic mouse
models of cerebral amyloidosis (Lacoste et al., 2013; Passos
et al., 2013). Also, increased B2R density was demonstrated by
3H-bradykinin binding assay in skin fibroblasts from patients
with AD compared to that from age-matched healthy controls
(Noda et al., 2003). In the present study, we showed that
arcAβ mice of amyloidosis have increased plasma bradykinin
levels as compared to NTLs at the endpoint of the study. The
arcAβ mouse model of cerebral amyloidosis exhibits cerebral
plaque deposition from 6 months-of-age together with strong
congophilic cerebral amyloid angiopathy (Knobloch et al., 2007)
and increased bradykinin plasma levels may likely be due to
vascular amyloid deposition.
BRs as Pharmacological Targets in AD
Previous studies using animal models of AD have described
BRs blockade as a potential treatment strategy for AD.
Pharmacological blockade of both BRs in transgenic mice over-
expressing amyloid precursor protein or mice infused with Aβ
has been shown to improve learning and memory formation.
B1R blockade mitigated cognitive deficits by B1R antagonist
des-Arg9[Leu8]-bradykinin in Aβ-treated mice (Prediger et al.,
2008) and in rat (Bitencourt et al., 2017), and by B1R antagonist
SSR240612 in Tg-SwDI mice of AD (Lacoste et al., 2013). B2R
blockade by HOE 140 protected against cognitive impartment in
Aβ-infused mice (Prediger et al., 2008; Bicca et al., 2015).
It has been described that B2Rs are constitutively expressed
and mediate most physiological actions of kinins, whereas
B1Rs are highly inducible upon inflammatory stimulation and
tissue injury (Marceau et al., 2002). Thus, the majority of
previous preclinical studies have focused on B1R inhibition.
However, it has been described that the expression of both
receptors is increased under pathological conditions related to
oxidative stress, pro-inflammatory stimuli (e.g., inflammation
and infection) as well as vasoactive peptides of the renin-
angiotensin system (Nokkari et al., 2018). Thus, we have
used noscapine a phthalideisoquinoline alkaloid, which is an
antagonist for both B1R and B2R (pA2 = 6.68) (Mahmoudian and
Mojaverian, 2001). We decided to provide the drug in drinking
water as an easy administrable way for chronic pharmacological
treatment, but which might have introduced variability in the
treatment effect due to different uptake of the drug by the mice.
Noscapine has been clinically approved as antitussive drug, and
has the advantage that it can be administered orally, that its
pharmacokinetics and metabolic fate are characterized, and that
it has low toxicity (Empey et al., 1979; Tsunoda and Yoshimura,
1979; Karlsson et al., 1990).
Blockade of B1R and B2R Ameliorates
Cerebrovascular Dysfunction
We used established functional MRI protocols to assess the effects
of noscapine treatment on cerebrovascular dysfunction in vivo
(Klohs et al., 2014; Ni et al., 2018a). Cerebrovascular dysfunction
is an early pathological event in patients with AD (Iturria-Medina
et al., 2016). The brain critically depends on the continuous
supply of oxygen and nutrients for proper cognitive function,
and thus CBF is a tightly regulated process. In a previous
study it was shown with Laser Doppler flowmetry in the J20
mouse model that blockade of B1R improves CBF (Lacoste et al.,
2013). We have assessed CBF using a non-invasive arterial spin
labeling technique. We showed a 25% reduction in CBF in the
cortex of approximately 17-months-old arcAβ mice compared
to age-matched NTLs. In a previous study using the same fMRI
technique we found normal CBV values in 6-months-old arcAβ
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FIGURE 5 | Immunohistochemical analysis of Aβ load and microglia activation. (A) Brain tissue sections of untreated and noscapine-treated NTLs and arcAβ mice
were stained for amyloid (6E10, red), microglia (Iba1, green) immunoreactivity in the cortex (ctx) and hippocampus (hippo) of untreated and noscapine-treated NTLs
and arcAβ mice, respectively. Scale bar = 400 µm. (B) Quantification of immunoreactivity. Data are present as mean ± standard deviation; Iba1: ionized
calcium-binding adapter molecule 1. ∗p < 0.05, two-way ANOVA with Tukey’s post hoc correction for multiple comparison. NTL (n = 5), NTL noscapine (n = 5),
arcAβ (n = 5), and arcAβ noscapine (n = 5).
mice and a 30% reduction in CBF in the cortex of 24-months-old
arcAβ mice compared to NTLs (Ni et al., 2018b), which indicates
that the severity of the CBF reduction increased with increasing
age in that mouse model. With perfusion MRI, we observed that
noscapine treatment reversed the pathological hypoperfusion in
the cortex and thalamus in arcAβ mice.
Cerebral vascular reactivity reflects the capacity of blood
vessels to dilate and is an important indicator of the brain
vascular reserve capacity. Dynamic measurement of CBV upon
acetazolamide challenge is commonly used in humans and
animals for quantification of CVR and has shown to be impaired
in AD patients and models of cerebral amyloidosis (Stoppe et al.,
1995; Mueggler et al., 2002; Princz-Kranz et al., 2010; Dumas
et al., 2012). Acetazolamide inhibits carbonic anhydrase, which
results into increased CBV, but its exact mode of action is not yet
clear (Vorstrup et al., 1984; Dumas et al., 2012). In our study we
observed a global reduction in CVR in the cortical and subcortical
regions in untreated arcAβ mice compared to NTLs. A previous
fMRI study has described a reduction of CVR in cortical regions
but not subcortical regions in 16-months-old arcAβ mice that
was aggravated with aging (Princz-Kranz et al., 2010). These
differences in CVR in subcortical regions of arcAβ mice might
be due to the fact that mice although being of the same strain
were from different colonies. Biological factors such as genetic
backgrounds (our arcAβ mice were derived from transgenic
mouse strain back-crossed to C57BL6 for over 10 generations
compared to mice in the previous study which had been on
a mixed genetic background) and environmental factors such
as housing conditions can affect the phenotype. In the current
study we found that treatment with noscapine ameliorated CVR
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FIGURE 6 | Meso Scale Discovery (MSD) analysis of Aβ load in TBS, SDS and FA fraction of mouse brain homogenates from untreated and noscapine-treated NTLs
and arcAβ mice (A) Aβ38; (B) Aβ40; (C) Aβ42. ∗∗∗p < 0.001, two-way ANOVA with Tukey’s post hoc correction for multiple comparison. NTL (n = 6), NTL noscapine
(n = 8), arcAβ (n = 7), and arcAβ noscapine (n = 4) mice.
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reduction in arcAβ mice, which is in line with a previous study
that blockade of B1R significantly ameliorated sensory-evoked
hemodynamic responses in the J20 mouse model (Lacoste et al.,
2013). As inhibition of BRs can affect the angiotensin system
(AbdAlla et al., 2001; Jing et al., 2012), we measured systolic and
diastolic blood pressure between groups. As we did not observe
differences in blood pressure values among groups, we ruled
out that the observed 1CBV differences were due to actions of
noscapine on the angiotensin system.
The findings from CVR and CBF measurement clearly
demonstrate that inhibition of B1R and B2R ameliorate
Aβ-induced cerebrovascular dysfunction. The molecular
mechanisms underlying cerebrovascular dysfunction in AD are
not well-understood and it can only be speculated how noscapine
treatment ameliorated hypoperfusion and reduced CVR in arcAβ
mice. It has been suggested that blockade of BRs antagonized the
production of vascular reactive oxygen species and inflammatory
cytokines (Lacoste et al., 2013; Nokkari et al., 2018), which might
have contributed to the restoration of the vascular reactivity
(Klohs et al., 2012).
Blockade of B1R and B2R Does Not Alter
Neuropathology
In addition to functional vascular effects of noscapine treatment,
we also assessed the effects on neuroinflammation and Aβ
pathology. Gliosis is an early phenomenon both in mouse models
of amyloidosis (Rodriguez-Vieitez et al., 2015; Lopez-Picon et al.,
2018) and in patients with AD (Heneka et al., 2015). Activated
microglia surrounding amyloid deposits and upregulated pro-
inflammatory cytokines have been reported in the arcAβ mice
(Knobloch et al., 2007; Klohs et al., 2012) and we have seen
also microglia activation in the brains of noscapine-treated and
untreated arcAβ mice.
B1R is involved in inflammation in the central nervous
system mainly through the activation of microglia (Asraf et al.,
2017) and astrocytes (Lacoste et al., 2013). However, the
effects of bradykinin inhibition on microglia and astrocytes
have been inconsistent, both suppression (Bitencourt et al.,
2017) and stimulation (Asraf et al., 2016) of neuroinflammation
has been reported, or showed no effect (Asraf et al., 2016).
Using measurements of Iba1 immunoreactivity in few selected
animals from each group, we found no effect of chronic oral
noscapine treatment on microglia activation. In the current
study, we have used Iba1 immunoreactivity as a rough estimate of
neuroinflammation and have not attempted to discriminate the
different types of microglia (resting and activated), which would
require a more elaborate histological analysis. In addition, other
markers of neuroinflammation (for example GFAP, CD68, etc.)
and larger groups of animals might be investigated.
Reports on the effect of B1R and B2R on Aβ load have also been
contradictory. B2R activation promoted α-secretase processing of
amyloid precursor protein in skin fibroblasts from patients with
AD, resulting in a lower production of Aβ (Nitsch et al., 1998).
B1R antagonist SSR240612 reduced Aβ deposition (Lacoste et al.,
2013) in Tg-SwDI mouse model of AD amyloidosis, while
another B1R antagonist R-715 treatment increased Aβ40 and
fibrillar Aβ deposition in both transgenic mouse models of AD,
Tg-SwDI (Passos et al., 2013) and 5 × familial mice (Asraf
et al., 2016). Aβ can in turn activate the release of kinins in
cultured endothelial cells (Joseph et al., 1999). In our study,
using immunohistochemical analysis of brain section and MSD
immunoassay of brain tissue we found no effect of inhibition of
B1R and B2R inhibition on cerebral Aβ load.
Methodological Considerations
The reported differences in the action of bradykinin receptor
inhibitors might be due to the affinity of individual inhibitors
to B1R and B2R, as well as other factors like pharmacokinetics,
biodistribution of the drug used, and the timing, dose and
duration of the treatment. In our study, we found amelioration
of cerebrovascular dysfunction with chronic oral noscapine
treatment, while the treatment seemed to have no effects on
cerebral Aβ load and microglia activation. In that context,
fMRI could constitute a more sensitive and earlier indicator of
treatment response than histological or biochemical assessment.
It might be, however, conceivable that a different dose of
noscapine or longer treatment periods might have also led to
detectable changes in neuropathology. In addition, we started
treatment in arcAβ mice at an advanced disease stage, which
limited the potential effect scale on the different read-outs.
Importantly, we have not used behavioral read-outs to assess
effects of noscapine treatment on the cognitive deficit in
arcAβ mice (Knobloch et al., 2007) and thus do not know if
noscapine has led to an improvement of cognitive function.
Thus, more extensive studies using additional behavioral read-
outs, and starting treatment at an early disease stage are needed
to demonstrate the full potential of noscapine treatment on
AD pathology.
CONCLUSION
Long-term oral noscapine treatment alleviates brain
hypoperfusion and restores CVR in an animal model
of amyloidosis as revealed by fMRI. Blocking BRs
represents a potential target for treatment of AD-associated
cerebrovascular dysfunction.
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